-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on TScan Therapeutics, Lowers Price Target to $10

Benzinga·05/07/2025 12:26:11
Listen to the news
HC Wainwright & Co. analyst Andres Maldonado maintains TScan Therapeutics (NASDAQ:TCRX) with a Buy and lowers the price target from $15 to $10.